Skye Bioscience, Inc. (OTCMKTS:SKYE) Sees Large Drop in Short Interest

Skye Bioscience, Inc. (OTCMKTS:SKYEGet Free Report) was the target of a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 100 shares, a drop of 66.7% from the October 15th total of 300 shares. Based on an average daily volume of 7,100 shares, the short-interest ratio is currently 0.0 days.

Skye Bioscience Stock Performance

Shares of SKYE stock opened at $1.70 on Friday. Skye Bioscience has a fifty-two week low of $1.52 and a fifty-two week high of $14.00. The stock has a 50 day simple moving average of $2.39 and a two-hundred day simple moving average of $0.84. The company has a market cap of $6.61 million, a P/E ratio of -0.17 and a beta of 0.91.

About Skye Bioscience

(Get Free Report)

Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.

Recommended Stories

Receive News & Ratings for Skye Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Skye Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.